Rebecca Jane Cox Brokstad
Professor, Head of the Influenza Centre
- E-mailRebecca.Cox@uib.no
- Phone+47 55 97 46 68+47 452 42 974
- Visitor Address5th Floor Laboratory BuildingJonas Leis vei 875021 BergenRoomOffice address: Room 114 Armauer Hansens Hus
- Postal AddressPostboks 78045020 Bergen
Academic article
- (2023). Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies. iScience.
- (2023). VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe. Vaccine.
- (2023). Risk assessment and antibody responses to SARS-CoV-2 in healthcare workers. Frontiers in Public Health. 13 pages.
- (2023). Post COVID-19 condition after delta infection and omicron reinfection in children and adolescents. EBioMedicine.
- (2023). Haemagglutination inhibition and virus microneutralisation serology assays: use of harmonised protocols and biological standards in seasonal influenza serology testing and their impact on inter-laboratory variation and assay correlation: A FLUCOP collaborative study. Frontiers in Immunology.
- (2023). Enhancing Public Health Communication Regarding Vaccine Trials: Design and Development of the Pan-European VACCELERATE Toolkit. JMIR Public Health and Surveillance.
- (2023). Durable immune responses after BNT162b2 vaccination in home-dwelling old adults. Vaccine: X. 1-11.
- (2023). An external quality assessment feasibility study; cross laboratory comparison of haemagglutination inhibition assay and microneutralization assay performance for seasonal influenza serology testing: A FLUCOP study. Frontiers in Immunology.
- (2022). Validation of a Harmonized Enzyme-Linked-Lectin-Assay (ELLA-NI) Based Neuraminidase Inhibition Assay Standard Operating Procedure (SOP) for Quantification of N1 Influenza Antibodies and the Use of a Calibrator to Improve the Reproducibility of the ELLA-NI With Reverse Genetics Viral and Recombinant Neuraminidase Antigens: A FLUCOP Collaborative Study. Frontiers in Immunology. 17 pages.
- (2022). Vaccination rates in Europe are not associated with online media intensity. JCOM - Journal of Science Communication. 15 pages.
- (2022). VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment. Vaccine. 4090-4097.
- (2022). Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants. npj Vaccines. 11 pages.
- (2022). The performances of three commercially available assays for the detection of SARS‐CoV‐2 antibodies at different time points following SARS‐CoV‐2 infection. Viruses. 1-11.
- (2022). The evolution of humoral immune responses to past and novel influenza virus strains gives evidence for antigenic seniority. Frontiers in Immunology. 1-15.
- (2022). Symptom Burden and Immune Dynamics 6 to 18 Months Following Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2): A Case-control Study. Clinical Infectious Diseases.
- (2022). Seasonal influenza vaccination expands hemagglutinin-specific antibody breadth to older and future A/H3N2 viruses. npj Vaccines. 10 pages.
- (2022). SARS CoV-2 Infection among Health Care Workers from Different Health Care Facilities in Western Norway: A Prospective, Cross-Sectional Study. Viruses. 8 pages.
- (2022). Human organotypic airway and lung organoid cells of bronchiolar and alveolar differentiation are permissive to infection by influenza and SARS-CoV-2 respiratory virus. Frontiers in Cellular and Infection Microbiology. 1-23.
- (2022). Harmonization and qualification of intracellular cytokine staining to measure influenza-specific CD4<sup>+</sup> T cell immunity within the FLUCOP consortium. Frontiers in Immunology. 14 pages.
- (2022). Harmonization and qualification of an IFN-γ Enzyme-Linked ImmunoSpot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium. Frontiers in Immunology. 14 pages.
- (2022). Factors that impact on recruitment to vaccine trials during a pandemic or epidemic: a qualitative evidence synthesis. Cochrane Database of Systematic Reviews. 13 pages.
- (2022). Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients. PLOS ONE. 16 pages.
- (2022). A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. Communications Medicine. 11 pages.
- (2022). A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease. International Journal of Molecular Sciences.
- (2021). Safety, Immunogenicity, Efficacy and Effectiveness of Inactivated Influenza Vaccines in Healthy Pregnant Women and Children Under 5 Years: An Evidence-Based Clinical Review. Frontiers in Immunology. 16 pages.
- (2021). Repeated Influenza Vaccination Boosts and Maintains H1N1pdm09 Neuraminidase Antibody Titers. Frontiers in Immunology. 1-11.
- (2021). Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response. npj Vaccines. 1-6.
- (2021). Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With In Vivo Protection. Frontiers in Immunology. 1-13.
- (2021). Lower antibiotic prescription rates in hospitalized COVID-19 patients than influenza patients, a prospective study. Infectious Diseases. 1-12.
- (2021). Long COVID in a prospective cohort of home-isolated patients. Nature Medicine. 1607-1613.
- (2021). Learning from the COVID-19 pandemic among migrants: An innovative, system-level, interdisciplinary approach is needed to improve public health . Scandinavian Journal of Public Health. 804-808.
- (2021). Humoral and cellular immune responses in critically ill influenza A/H1N1-infected patients. Scandinavian Journal of Immunology. 1-9.
- (2021). Functional and Binding H1N1pdm09-Specific Antibody Responses in Occasionally and Repeatedly Vaccinated Healthcare Workers: A Five-Year Study (2009-2014). Frontiers in Immunology.
- (2021). Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: A case-ascertained study. The Lancet Regional Health - Europe. 9 pages.
- (2021). Assay harmonization and use of biological standards to improve the reproducibility of the hemagglutination inhibition assay: A FLUCOP collaborative study. mSphere. 1-18.
- (2020). Viral antigens elicit augmented immune responses in primary Sjögren's syndrome. Rheumatology. 1651-1661.
- (2020). Third human challenge trial conference, Oxford, United Kingdom, February 6–7, 2020, a meeting report. Biologicals (Print). 41-52.
- (2020). SARS-CoV-2-specific neutralizing antibody responses in Norwegian healthcare workers after the first wave of COVID-19 pandemic: a prospective cohort study. Journal of Infectious Diseases.
- (2020). Responsiveness to influenza vaccination correlates with nkg2c-expression on nk cells. Vaccines. 1-18.
- (2020). Point-of-care influenza testing impacts clinical decision, patient flow and length of stay in hospitalized adults. Journal of Infectious Diseases. 97-108.
- (2020). Live-attenuated influenza vaccine induces tonsillar follicular T helper cell responses that correlate with antibody induction. Journal of Infectious Diseases. 21-32.
- (2020). Human antibodies targeting influenza B virus neuraminidase active site are broadly protective. Immunity. 852-863.
- (2020). Early Induction of Cross-Reactive CD8+ T-Cell Responses in Tonsils After Live-Attenuated Influenza Vaccination in Children. Journal of Infectious Diseases. 1528-1537.
- (2019). Vitamin D Deficiency is Associated with Increased Use of Antimicrobials among Preschool Girls in Ethiopia. Nutrients. 1-14.
- (2019). No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination. Vaccine: X. 1-8.
- (2019). Meeting report and review: Immunological assays and correlates of protection for next-generation influenza vaccines. Influenza and Other Respiratory Viruses. 1-7.
- (2019). Low temperature and low UV indexes correlated with peaks of influenza virus activity in Northern Europe during 2010-2018. Viruses. 1-10.
- (2019). Functional immune response to influenza H1N1 in children and adults after live attenuated influenza virus vaccination. Scandinavian Journal of Immunology. 1-12.
- (2019). Common nodes of virus-host interaction revealed through an integrated network analysis. Frontiers in Immunology. 12 pages.
- (2018). T follicular-like helper cells in the peripheral blood of patients with primary Sjögren's syndrome. Scandinavian Journal of Immunology. 1-15.
- (2018). Novel activities of safe-in-human broad-spectrum antiviral agents. Antiviral Research. 174-182.
- (2018). Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine. Vaccine. 2213-2219.
- (2018). Impact of erythrocyte species on assays for influenza serology. Journal of Preventive Medicine and Hygiene (JPMH). E1-E7.
- (2018). Augmented CD4+ T-cell and humoral responses after repeated annual influenza vaccination with the same vaccine component A/H1N1pdm09 over 5 years. npj Vaccines. 10 pages.
- (2018). Antibody responses to influenza A/H1N1pdm09 virus after pandemic and seasonal influenza vaccination in healthcare workers: A 5-year follow-up study. Clinical Infectious Diseases. 382-392.
- (2018). Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy. European Journal of Neurology. 527-534.
- (2018). Antibody levels in a cohort of pregnant women after the 2009 influenza A(H1N1) pandemic: Waning and association with self-reported severity and duration of illness. Influenza and Other Respiratory Viruses. 191-200.
- (2017). Mucosal administration of cycle-di-nucleotide-adjuvanted virosomes efficiently induces protection against influenza H5N1 in mice. Frontiers in Immunology. 1-15.
- (2017). Influenza virus hemagglutinin stalk-specific antibodies in human serum are a surrogate marker for in vivo protection in a serum transfer mouse challenge model. mBio. 1-13.
- (2017). Influenza A haemagglutinin specific IgG responses in children and adults after seasonal trivalent live attenuated influenza vaccination. Vaccine. 5666-5673.
- (2017). High prevalence of humoral and cellular immunity to influenza viruses in preschool children living in Addis Ababa, Ethiopia. Open Forum Infectious Diseases. 6 pages.
- (2017). Distinct T and NK cell populations may serve as immune correlates of protection against symptomatic pandemic influenza A(H1N1) virus infection during pregnancy. PLOS ONE. 14 pages.
- (2017). Boosting of cross-reactive and protection-associated T cells in children after live attenuated influenza vaccination. Journal of Infectious Diseases. 1527-1535.
- (2017). A DNA vaccine that targets hemagglutinin to antigen-presenting cells protects mice against H7 influenza. Journal of Virology. 1-13.
- (2016). Self-reported influenza vaccination and protective serum antibody titers in a cohort of COPD patients. Respiratory Medicine. 53-59.
- (2016). Salivary IgA from the sublingual compartment as a novel noninvasive proxy for intestinal immune induction. Mucosal Immunology. 884-893.
- (2016). Pulmonary changes in Norwegian fatal cases of pandemic influenza H1N1 (2009) infection: a morphologic and molecular genetic study. Influenza and Other Respiratory Viruses. 525-531.
- (2016). Long-term maintenance of the influenza-specific cross-reactive memory CD4+ T-cell responses following repeated annual influenza vaccination. Journal of Infectious Diseases. 740-749.
- (2016). Live attenuated influenza vaccine in children induces b-cell responses in tonsils. Journal of Infectious Diseases. 722-731.
- (2016). Interpandemic (Seasonal) influenza. ERS Monograph. 35-64.
- (2016). Humoral, T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies. Vaccine. 3576-3583.
- (2016). Epitope specific T-cell responses against influenza A in a healthy population. Immunology. 165-177.
- (2016). Dissecting the hemagglutinin head and stalk-specific IgG antibody response in healthcare workers following pandemic H1N1 vaccination. npj Vaccines.
- (2016). Comparative analysis of influenza A(H3N2) virus hemagglutinin specific IgG subclass and IgA responses in children and adults after influenza vaccination. Vaccine. 191-198.
- (2015). Validation of Single Radial Haemolysis assay: A reliable method to measure antibodies against influenza viruses. Journal of Immunological Methods (JIM). 95-101.
- (2015). Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. mBio. 13 pages.
- (2015). The expression of B & T cell activation markers in children’s tonsils following live attenuated influenza vaccine. Human Vaccines & Immunotherapeutics. 1663-1672.
- (2015). Single dose vaccination of the ASO3-adjuvanted A (H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains. Human Vaccines & Immunotherapeutics. 1654-1662.
- (2015). Persistence and avidity maturation of antibodies to A(H1N1)pdm09 in healthcare workers following repeated annual vaccinations. Vaccine. 4146-4154.
- (2015). Need for more targeted measures - Only less severe hospital-associated infections declined after introduction of an infection control program. Journal of Infection and Public Health. 282-290.
- (2015). Mortality related to hospital-associated infections in a tertiary hospital; repeated cross-sectional studies between 2004-2011. Antimicrobial Resistance and Infection Control. 1-8.
- (2015). Matrix M H5N1 vaccine induces cross-H5 clade humoral immune responses in a randomized clinical trial and provides protection from highly pathogenic influenza challenge in ferrets. PLOS ONE.
- (2015). Longevity of B-cell and T-cell responses after live attenuated influenza vaccination in children. Journal of Infectious Diseases. 1541-1549.
- (2015). Intranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge. Human Vaccines & Immunotherapeutics. 1235-1243.
- (2015). Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines. Vaccines. 373-389.
- (2015). Induction of local secretory IgA and multifunctional CD4+ T-helper cells following intranasal immunization with a H5N1 whole inactivated influenza virus vaccine in BALB/c mice. Scandinavian Journal of Immunology. 305-317.
- (2015). Immune responses in acute and convalescent patients with mild, moderate and severe disease during the 2009 influenza pandemic in Norway. PLOS ONE. 16 pages.
- (2014). The Influence of Tonsillectomy on Total Serum Antibody Levels. Scandinavian Journal of Immunology. 377-379.
- (2014). Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination. Vaccine. 4550-4557.
- (2014). Matrix M™ adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4+ T cell responses in man. Human Vaccines & Immunotherapeutics. 2408-2416.
- (2014). Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge. PLOS ONE.
- (2014). Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. Journal of Virology. 13260-13268.
- (2014). Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: An explorative study. Multiple Sclerosis. 1074-1080.
- (2014). Experimental infection of healthy volunteers with enterotoxigenic Escherichia coli wild-type strain TW10598 in a hospital ward. BMC Infectious Diseases. 9 pages.
- (2014). Divergent H7 immunogens offer protection from H7N9 virus challenge. Journal of Virology. 3976-3985.
- (2014). An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans. Clinical and Vaccine Immunology. 1153-1163.
- (2013). A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine. Influenza and Other Respiratory Viruses. 1181-1193.
- (2012). The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine. Influenza and Other Respiratory Viruses. 90-100.
- (2012). The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants. Human Vaccines & Immunotherapeutics. 653-661.
- (2012). T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. Journal of Infectious Diseases. 158-166.
- (2012). Influenza-like illness in general practice in Norway: clinical course and attitudes towards vaccination and preventive measures during the 2009 pandemic. Family Practice. 139-146.
- (2012). A(H1N1)pdm09 Vaccination of Health Care Workers: Improved Immune Responses in Low Responders Following Revaccination. Journal of Infectious Diseases. 1660-1669.
- (2011). Pandemic influenza vaccination of hypogammaglobulinemic patients induces normal or elevated influenza-specific CD4+Th1-cell responses. Influenza and Other Respiratory Viruses. 376-379.
- (2011). Pandemic Influenza Vaccination Elicits Influenza-Specific CD4(+) Th1-cell Responses in Hypogammaglobulinaemic Patients: Four case reports. Scandinavian Journal of Immunology. 210-218.
- (2011). Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza and Other Respiratory Viruses. 426-437.
- (2011). Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4(+) cells and strong mucosal and systemic antibody responses in mice. Vaccine. 4973-4982.
- (2011). Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP. PLOS ONE. 12 pages.
- (2011). Evaluation of a virosomal H5N1 vaccine formulated with Matrix M (TM) adjuvant in a phase I clinical trial. Vaccine. 8049-8059.
- (2010). An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine. 266-273.
- (2009). Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice. Vaccine. 7367-7376.
- (2009). A pilot study of the immune response to whole inactivated avian influenza H7N1 virus vaccine in mice. Influenza and Other Respiratory Viruses. 21-28.
- (2009). A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine. 1889-1897.
- (2009). A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models. Influenza and Other Respiratory Viruses. 107-117.
- (2007). Quality and kinetics of the antibody response in mice after three different low-dose influenza virus vaccination strategies. Clinical and Laboratory Immunology. 978-983.
- (2007). A comparison of the humoral and cellular immune responses at different immunological sites after split influenza virus vaccination of mice. Scandinavian Journal of Immunology. 14-21.
- (2006). The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB/c mice. Vaccine. 6585-6587.
- (2006). The humoral and cellular responses induced locally and systematically after parenteral influenza vaccination in man. Vaccine. 6577-6580.
- (2006). Impact of influenza vaccine formulation with a detailed analysis of the cytokine response. Scandinavian Journal of Immunology. 467-475.
- (2005). Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scandinavian Journal of Immunology. 36-44.
- (2005). Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice. Scandinavian Journal of Immunology. 342-352.
- (2002). Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa. Journal of Infectious Diseases. 878-884.
- (2002). Non-lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication. Scandinavian Journal of Immunology. 14-23.
- (2001). The effect of zanamivir treatment on the early immune response to influenza vaccination. Vaccine. 4743-4749.
- (2001). Non-lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication. Scandinavian Journal of Immunology. 14-23.
- (2001). High prevalence of influenza specific antibody secreting cells in nasal mucosa. Scandinavian Journal of Immunology. 243-247.
Academic lecture
- (2022). SARS CoV-2 vaccines, what have we learnt and what is the future .
- (2022). Covid-19 vaccine evaluation.
- (2021). Pre-existing immunity and correlates of protection for Influenza.
- (2021). Influenza and SARS-CoV-2 vaccines and the young immune system: should we vaccinate children.
- (2021). Covid-19 i Bergen.
- (2020). Influensa.
- (2020). Case study: Influenza; impact of pre-existing immunity on study end points .
- (2020). COVID-19 in the community and health care system in Bergen, Norway.
- (2020). COVID-19 in the community and health care system in Bergen .
- (2019). Immune responses to influenza A/H1N1pdm09 virus after adjuvanted pandemic and seasonal influenza vaccination in healthcare workers.
- (2019). Critical Nodes of Viral Modulation Revealed Through an Integrated Network Analysis of Host-Virus Interaction Landscape.
- (2018). Using human influenza vaccine studies to define next generation vaccines .
- (2018). Subject selection and screening for susceptibility to challenge.
- (2018). Should we vaccinate health care workers against influenza annually?
- (2018). Should we annually vaccinate health care workers against influenza?
- (2018). Hvorfor trenger vi fremdeles vaksiner? og Influensa en evig kamp. .
- (2015). Cellular immune responses after live attenuated influenza vaccination in children, a clinical trial.
- (2014). The Norwegian Influenza cohort study (NorFlu): immune responses in H1N1 pdm exposed versus non-exposed pregnant women.
- (2014). The Norwegian Influenza cohort (NorFlu): immune responses in pdmH1N1 exposed versus non-exposed pregnant women.
- (2014). Perinatal outcomes and children’s health after prenatal exposure to influenza infection and vaccination.
- (2005). The humoral and cellular responses induced locally and systemically after parenteral influenza vaccination in man.
- (2004). The antibody response to parenteral influenza vaccination � A review of specificity, magnitude, rapidity and shortcomings.
- (2003). The local and systemic immune response to parenterally administered inactivated influenza vaccine.
- (2003). The local and systemic immune response to parenterally administered inactivated influenza vaccine.
- (2002). Influenzaantigenspecific cells in human nasal mucosa.
- (2002). Influenza-specific antibody producing cells in human nasal mucosa.
- (2002). Influenza-specific antibody producing cells in human nasal mucosa.
- (2002). Influenza specific antibodysecreting cells in nasal mucosa, prior to and after vaccination.
- (2002). Influenza specific antibody secreting cells in nasal mucosa.
- (2001). The level of influenzaspecific antibodysecreting cells in nasal mucosa, prior to an after vaccination.
- (2001). The effect of relenza treatment on the early immune response induced after influenza vaccination.
- (2001). The basal level of influenza specific antibody secreting cells in healthy subjects.
- (2001). Influenza specific antibody secreting cells (I-ASC)in human nasal mucosa. Relation to tonsil, blood and parenteral vaccination.
- (2001). Influensaantigenspecifika, antikroppsproducerande lymfocyter i human nasal slemhinne.
- (2001). DNA vaccination with HA or NP encoding plasmids results in rapid viral clearance after viral challenge.
- (2001). Antibodies from lymphocytes used as diagnostic markers: A novel approach.
Editorial
- (2022). Editorial: Pandemic influenza vaccine approaches: Current status and future directions. Frontiers in Immunology.
- (2013). Correlates of protection to influenza virus, where do we go from here? Human Vaccines & Immunotherapeutics. 405-408.
- (2012). The mucosal vaccine quandary Intranasal vs. sublingual immunization against influenza. Human Vaccines & Immunotherapeutics. 690-694.
- (2006). Pandernic influenza vaccine development: time is of the essence. Expert Review of Vaccines. 603-606.
- (2006). Pandemic influenza vaccine development: time is of the essence. Expert Review of Vaccines.
Popular scientific article
- (2020). COVID-19 og jakta på ein vaksine. Naturen.
- (2018). Pandemivaksinen i 2009-en forberedelse til neste influensapandemi. Best practices.
Feature article
- (2020). Not just antibodies: B cells and T cells mediate immunity to COVID-19. Nature reviews. Immunology.
- (2020). Det er ikke bare antistoffer som beskytter mot covid-19. Aftenposten (morgenutg. : trykt utg.).
- (2020). CoVid-19; Derfor vil ikke dødeligheten være stor hvis viruset spres i Norge Norsk helsevesen er godt forberedt på at Wuhan-viruset kan spre seg til landet og beredskapen er på plass. Bergens Tidende.
- (2018). Få en influensafri jul! Bergens Tidende.
- (2017). Nok tro og folelser na. Bergens Tidende.
- (2017). Gravide – se opp for fake news! Bergens Tidende.
- (2015). Sølje Bergman er farligere for barn enn vaksiner. Bergens Tidende.
Doctoral dissertation
- (2019). Live Attenuated Influenza Vaccine (LAIV) Immunization in Children and Adults: Lesson for Development of Universal Influenza Vaccine.
- (2018). Long-term immune response after pandemic and seasonal influenza vaccination in healthcare workers.
- (2016). Immune response to influenza after vaccination and infection.
Documentary
- (2013). Målet er en livsvarig supervaksine mot influensa.
- (2013). Forskning på ny influensa vaksine for barn.
Academic chapter/article/Conference paper
- (2004). The kinetics of the systemic and local immune response to parenteral influenza vaccination. 4 pages.
- (2004). The immune response to H7N1 whole virus vaccine in mice. 4 pages.
- (2004). Comparison of the humoral immune response to split and whole virus vaccines in mice. 4 pages.
- (2003). Detection of antibodies to influenza virus in human mucosal tissues and fluids.
Abstract
- (2011). Influenza Specific T-Cell Responses Predict Later Neutralizing Antibody Titres in a Phase 1 Clinical Trial of a Virosomal H5N1 Vaccine Adjuvanted with Matrix-M. Scandinavian Journal of Immunology. 355-355.
- (2011). Comparison of Different Routes of Administration for Influenza Vaccines in a Murine Model. Scandinavian Journal of Immunology. 351-351.
Errata
- (2023). Author Correction: Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants (npj Vaccines, (2022), 7, 1, (174), 10.1038/s41541-022-00586-7). npj Vaccines.
Academic literature review
- (2022). COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment – Meeting report from an isirv-WHO virtual conference. Antiviral Research.
- (2021). A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future. Vaccine. 6573-6584.
- (2020). Prospects and challenges in the development of universal influenza vaccines. Vaccines. 1-12.
- (2018). Influensa-alltid relevant . Bestpractice Onkologi/Hematologi. 15-17.
- (2018). Improving influenza vaccines: challenges to effective implementation. Current Opinion in Immunology. 88-95.
- (2017). Immune responses after live attenuated influenza vaccination . Human Vaccines & Immunotherapeutics. 571-578.
- (2013). The emergence of H7N9 viruses: A chance to redefine correlates of protection for influenza virus vaccines. Expert Review of Vaccines. 1369-1372.
- (2009). Pandemic influenza vaccines - the challenges. Viruses. 1089-1109.
- (2007). Influenza: the virus and prophylaxis with inactivated influenza vaccine in "at risk" groups, including COPD patients. The International Journal of Chronic Obstructive Pulmonary Disease. 229-240.
- (2004). Influenza virus: Immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scandinavian Journal of Immunology. 1-15.
Article in business/trade/industry journal
- (2021). SARS-CoV-2; livssyklus, mutasjoner, immunreaksjoner og vaksiner. Bioingeniøren.
- (2021). SARS-CoV-2; Mutasjoner og Varianter. . Bioingeniøren.
- (2018). Immunrespons etter levende svekket influensavksine. Best practices.
More information in national current research information system (CRIStin)